While, monoclonalantibodyagainstCD20antigen on the membrane ofB-cell NHLsand normal B-lymphocyte showed satisfactory curative effect in clinical treatment of NHL.
Benlysta is delivered directly into a vein (intravenous infusion) and is the first inhibitor designed to target B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells thought to be a problem in lupus.